Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 44 weeks
Summary
This trial is testing a new drug called ABBV-181 in people with HIV who are stopping their usual treatment. The goal is to see if the drug is safe and effective, and how it affects the immune system and the virus.
Eligible Conditions
- HIV
- HIV/AIDS
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 44 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 44 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Area Under the Curve (AUCtau)
Half-life (t1/2)
Maximum Observed Concentration (Cmax)
+5 moreTrial Design
5Treatment groups
Experimental Treatment
Placebo Group
Group I: Stage 2: Arm EExperimental Treatment1 Intervention
Participants will receive ABBV-181 dose C.
Group II: Stage 1: Arm CExperimental Treatment1 Intervention
Participants will receive ABBV-181 dose B.
Group III: Stage 1: Arm BExperimental Treatment1 Intervention
Participants will receive ABBV-181 dose A.
Group IV: Stage 2: Arm DPlacebo Group1 Intervention
Participants will receive Placebo.
Group V: Stage 1: Arm APlacebo Group1 Intervention
Participants will receive placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-181
2013
Completed Phase 1
~500
Find a Location
Who is running the clinical trial?
AbbVieLead Sponsor
1,023 Previous Clinical Trials
520,248 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
444 Previous Clinical Trials
160,734 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger